The Effect of Regular Aspirin Use on the Risk of Advanced Prostate Cancer and Survival

According to a noteworthy study presented at the 2016 Genitourinary Cancers Symposium held in America last week, regular aspirin use may reduce the risk of aggressive prostate cancer. The risk of death may also be significantly reduced in men with prostate cancer who regularly use aspirin after diagnosis.
Aspirin is normally associated with heart health. However, numerous studies on aspirin use in cancer have been conducted in recent years. This article concerns the relationship between aspirin use and prostate cancer. Prostate cancer is usually a slowly developing or painless disease, but many deaths due to prostate cancer occur each year. A study presented at the 2016 Genitourinary Cancers Symposium reported a 24% reduction in the risk of developing advanced prostate cancer in men without a prostate cancer diagnosis who regularly used aspirin. Regular aspirin use was also shown to reduce the risk of death by 39% in men diagnosed with the disease. However, regular aspirin use before diagnosis was shown to provide no significant benefit in preventing locally advanced or high-grade prostate cancer.
The study followed men registered between 1982-2009, totaling 22.071 participants. Participants’ prostate cancer status and aspirin use were reviewed annually through questionnaires, and hospital records were examined. The research initially examined the relationship between regular aspirin use and fatal or metastatic prostate cancer (called “lethal” in the study). Regular aspirin use was defined as 3 tablets or more per week.
After 27 years of observation, there were 403 lethal cases among a total of 3193 men who developed prostate cancer. In the study, which accounted for age, body mass index, race and smoking, the risk of developing the disease was found to be 24% lower in men without prostate cancer who regularly used aspirin.
When men diagnosed with prostate cancer were examined, regular aspirin users were found to have an almost 40% lower risk of death from prostate cancer.
The researchers thought aspirin’s benefits might arise from its role in inhibiting platelets. It was proposed that platelets probably prevent the immune system from recognizing circulating cancer cells, while aspirin may enable the immune system to recognize cancer cells by reducing platelet function. Some animal studies support this hypothesis. This also helps explain why it is effective only against widespread/metastatic prostate cancer and not against regional cancer.
The main limitation of this study was changes in the frequency and dose of aspirin use among participants observed for almost more than 30 years. In the study, which began in 1982, participants initially used 325 mg of aspirin daily. However, when the cardiovascular (heart disease) benefits of low-dose aspirin were observed 5 years after this study, the required dose was determined as 81 mg, and the ideal dose has not been fully clarified.
This study showed that aspirin might also be beneficial in diseases other than colorectal (large bowel) cancers and heart diseases. It should be remembered that the research findings came from an observational study. Such studies are undoubtedly intriguing. Future research will clarify more clearly which cancer types benefit from aspirin and what its ideal dose should be.
Sources
Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.
2016 Genitourinary Cancers Symposium. J Clin Oncol 34, 2016 (suppl 2S; abstr 306)
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.